SynthesisHuman vaccines & immunotherapeutics2015
Evaluation of the economic burden of Herpes Zoster (HZ) infection.
Synthesis in Human vaccines & immunotherapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of bloodletting therapy for acute herpes zoster: a systematic review and meta-analysis.Frontiers in neurology · 2025Pooled it
- Indirect costs associated with skin infectious disease in children: a systematic review.BMC health services research · 2021Pooled it
- Unlocking herpes zoster vaccination value in Finland: return on investment and actuarial model.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Estimation of Costs Related to the Management of Herpes Zoster and its Complications in Vietnam: A Medical Chart Review.Infectious diseases and therapy · 2026Article
- Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil.Human vaccines & immunotherapeutics · 2025Article
- Demographical and Clinical Characteristics, Risk Factors, and Prognosis of Adult Patients with Herpes Zoster in Türkiye: A Retrospective, Multi-Center Study (VARICOMP-Adult Study).Infectious disease reports · 2025Article
- Knowledge, Attitudes, and Practices Regarding Herpes Zoster Vaccination Among Primary Healthcare Physicians: A Cross-sectional Survey in Jazan, Saudi Arabia.Oman medical journal · 2025Article
- The Economic Burden of Herpes Zoster in Individuals Aged 50 Years or Older and Those With Underlying Conditions in Italy.Open forum infectious diseases · 2025Article
- Challenges and Opportunities for Adult Vaccine Coverage: Insights for Healthcare Professionals Focusing on Herpes Zoster in Mexico.Vaccines · 2024Article
- Characteristics and economic burden of hospitalized patients with herpes zoster in China, before vaccination.Human vaccines & immunotherapeutics · 2023Article
- Article
- Herpes zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in New Zealand: a retrospective cohort study.The Lancet regional health. Western Pacific · 2023Article
- Article
- Association of asthma and herpes zoster, the role of vaccination: A literature review.Immunity, inflammation and disease · 2022Review
- External Therapy of Chinese Medicine for Herpes Zoster: A Systematic Review and Meta-Analysis.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Intravenous Administration of Vitamin C in the Treatment of Herpes Zoster-Associated Pain: Two Case Reports and Literature Review.Pain research & management · 2020Review
- Epidemiology of herpes zoster in the State of Qatar, 2012-2017.Qatar medical journal · 2020Article
- Burden of Herpes Zoster in the Japanese Population with Immunocompromised/Chronic Disease Conditions: Results from a Cohort Study Claims Database from 2005-2014.Dermatology and therapy · 2019Article
- The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy.Open forum infectious diseases · 2019Article
- Varicella zoster virus vaccines: an update.ImmunoTargets and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main objective of this systematic review was to evaluate the economic burden of Herpes Zoster (HZ) infection. The review was conducted in accordance with the standards of the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" guidelines. The following databases were accessed: ISI/Web of Knowledge (WoS), MEDLINE/PubMed, Scopus, ProQuest, the Cochrane Library and EconLit. Specific literature on health economics was also manually inspected. Thirty-three studies were included. The quality of the studies assessed in accordance with the Consolidated Health Economic Evaluation Reporting Standards checklist was good. All studies evaluated direct costs, apart from one which dealt only with indirect costs. Indirect costs were evaluated by 12 studies. The economic burden of HZ has increased over time. HZ management and drug prescriptions generate the highest direct costs. While increasing age, co-morbidities and drug treatment were found to predict higher direct costs, being employed was correlated with higher indirect costs, and thus with the onset age of the disease. Despite some differences among the selected studies, particularly with regard to indirect costs, all concur that HZ is a widespread disease which has a heavy social and economic burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.